Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 9:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 369 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Transplant;Failure,Kidney Clear all
Completed Not applicable Interventional Results available

Clinical Evaluation of a Vascular Venous Anastomotic Connector [InterGraft VIG-only Study]

NCT02532621
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Venous InterGraft Connector, sutured arterial anastomosis of an implanted vascular graft for hemodialysis, hemodialysis
Device · Procedure
Lead sponsor
Phraxis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
10
States / cities
Dothan, Alabama • Cartersville, Georgia • Macon, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 3, 2026, 9:32 AM EDT
Terminated Not applicable Interventional Results available

Safety and Efficacy of Angiotech Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access

NCT00448708
View directory record Official record
Conditions
Kidney Diseases, ESRD
Interventions
Vascular Wrap Paclitaxel-Eluting Mesh, Lifespan® ePTFE Vascular Graft
Device
Lead sponsor
Angiotech Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
33
States / cities
Birmingham, Alabama • Fresno, California • Inglewood, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 3, 2026, 9:32 AM EDT
Completed No phase listed Observational

Desensitization Protocol for Deceased Donor List

NCT01642225
View directory record Official record
Conditions
Transplant; Failure, Kidney
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
7 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Oct 3, 2026, 9:32 AM EDT
Terminated Not applicable Interventional

A Pilot Study To Evaluate The CreatiVasc Hemoaccess Valve System In Patients Requiring Arteriovenous Graft Placement

NCT01644526
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Hemoaccess Valve System
Device
Lead sponsor
Diaxamed LLC
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 3, 2026, 9:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-gene-nutraceutical Interactions of Cannabidiol and Tacrolimus

NCT05490511
View directory record Official record
Conditions
CBD, Transplant Complication, Kidney Disease, Chronic
Interventions
Tacrolimus single dose, Epidiolex single dose, Epidiolex steady-state and tacrolimus single dose
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 3, 2026, 9:32 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant

NCT03380962
View directory record Official record
Conditions
Kidney Failure, Chronic, End-Stage Renal Disease, Transplant Glomerulopathy, Transplant;Failure,Kidney, Kidney Transplant Failure and Rejection, Antibody-mediated Rejection, Kidney Transplant; Complications
Interventions
Clazakizumab
Drug
Lead sponsor
Stanley Jordan, MD
Other
Eligibility
15 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 3, 2026, 9:32 AM EDT
Completed Not applicable Interventional Results available

Reducing Disparities in Living Donor Transplant Among African Americans

NCT03819686
View directory record Official record
Conditions
Kidney Transplant
Interventions
Living ACTS website, Standard transplant education procedures
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 70 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 3, 2026, 9:32 AM EDT
Recruiting Phase 2 Interventional

Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency

NCT04240054
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, Isatuximab, Cyclophosphamide, Dexamethasone
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 3, 2026, 9:32 AM EDT
Withdrawn Phase 2 Interventional

Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients

NCT04531592
View directory record Official record
Conditions
Acute Kidney Injury, Ischemia Reperfusion Injury
Interventions
Valproic acid, Isotonic saline solution
Drug
Lead sponsor
Westat
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
San Francisco, California • Denver, Colorado • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 3, 2026, 9:32 AM EDT
Completed Not applicable Interventional Results available

Improving Chronic Disease Management With Pieces

NCT02587936
View directory record Official record
Conditions
Chronic Kidney Disease, Diabetes, Hypertension, High BP, Type 2 Diabetes
Interventions
Collaborative Model of Primary care and Subspecialty care
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
18,268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
4
States / cities
Farmington, Connecticut • Arlington, Texas • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 3, 2026, 9:32 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD

NCT07224763
View directory record Official record
Conditions
ESRD (End-Stage Renal Disease), Kidney Transplantation, Xenotransplantation
Interventions
GGTA1 KO Thymokidney
Biological
Lead sponsor
United Therapeutics
Industry
Eligibility
40 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2076
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 3, 2026, 9:32 AM EDT
Completed Phase 1Phase 2 Interventional

Transplant and Addiction Project (TAP) - 1

NCT00249652
View directory record Official record
Conditions
End Stage Liver Disease, End Stage Renal Disease, Substance-Related Disorders
Interventions
TAP, TAU
Behavioral · Other
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
3
States / cities
New York, New York • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 3, 2026, 9:32 AM EDT
Withdrawn Not applicable Interventional

Improving Access to Renal Transplantation for Underserved Black Communities

NCT06707038
View directory record Official record
Conditions
Kidney Transplant, ESRD (End Stage Renal Disease)
Interventions
AATAP intervention
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 3, 2026, 9:32 AM EDT
Completed Phase 4 Interventional Results available

Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients

NCT00224055
View directory record Official record
Conditions
Anemia, Iron-Deficiency, Kidney Failure, Chronic
Interventions
Sodium Ferric Gluconate Complex in Sucrose Injection, Ferrous sulfate tablets
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
23
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2012 · Synced Oct 3, 2026, 9:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation

NCT01178216
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Rituxan
Biological
Lead sponsor
Stanley Jordan, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Oct 3, 2026, 9:32 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Continuous Renal Replacement Therapy in the Setting of Orthotopic Liver Transplant

NCT01619449
View directory record Official record
Conditions
Acute Kidney Injury, Liver Disease, Chronic Kidney Disease, End Stage Kidney Disease
Interventions
Renal replacement therapy
Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 3, 2026, 9:32 AM EDT
Completed No phase listed Observational

Effectiveness of NephroCheckTM Test to Predict Acute Kidney Injury Following Advanced Cardiac Replacement Therapies

NCT02827448
View directory record Official record
Conditions
Acute Kidney Injury, Heart Failure
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Oct 3, 2026, 9:32 AM EDT
Terminated Phase 1Phase 2 Interventional

Prevention of Vascular Access Graft Failure in Patients With Chronic Renal Failure Requiring Hemodialysis

NCT00086164
View directory record Official record
Conditions
Hyperplasia, Chronic Renal Failure
Interventions
edifoligide (E2F Decoy)
Drug
Lead sponsor
Anesiva, Inc.
Industry
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
21
States / cities
Los Angeles, California • Hudson, Florida • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2005 · Synced Oct 3, 2026, 9:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus

NCT03760263
View directory record Official record
Conditions
Transplant;Failure,Kidney
Interventions
Tacrolimus
Drug
Lead sponsor
Sentara Norfolk General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 3, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Results available

Bone Mass and Strength After Kidney Transplantation

NCT02224144
View directory record Official record
Conditions
End Stage Renal Disease, Kidney Transplantation, Bone Loss, Fractures, Vascular Calcifications
Interventions
Vitamin D3, Calcitriol, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 3, 2026, 9:32 AM EDT
Terminated Phase 3 Interventional Results available

Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients

NCT00311311
View directory record Official record
Conditions
Atherosclerosis, Kidney Failure
Interventions
tacrolimus, mycophenolate mofetil, prednisone, sirolimus
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2013 · Synced Oct 3, 2026, 9:32 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)

NCT05092347
View directory record Official record
Conditions
Chronic Kidney Disease (CKD)
Interventions
Vonsetamig
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 3, 2026, 9:32 AM EDT
Completed Not applicable Interventional

iChoose Decision Kidney Aid for End-Stage Renal Disease Patients

NCT02235571
View directory record Official record
Conditions
End-Stage Kidney Disease, Kidney Failure, Chronic, Kidney Transplantation
Interventions
iChoose Kidney Decision Aid
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Atlanta, Georgia • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 3, 2026, 9:32 AM EDT
Completed Phase 4 Interventional Results available

Preop Digifab in CABG to Reduce Ouabain Levels and Prevent AKI

NCT03810417
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Digoxin Antibodies Fab Fragments, Placebo, Baseline EO > 360 pM, EO < 360 pM
Drug · Other · Diagnostic Test
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 3, 2026, 9:32 AM EDT